CLINICAL PHENOMENA IN SCHIZOPHRENIA--QUANTIFICATION IN A EFFORT TO SUBTYPE

尽管精神分裂症的临床表现千差万别，但它 临床医生仍然很难设计新的治疗方法或预测 易受负面结果影响(包括药物副作用) 根据疾病的体征和症状。通过将重点放在某些方面 精神分裂症的临床特点我们设计了一系列 实验性药物治疗。这涉及到这样一个概念，即 障碍与认知能力受损有关。因此，我们有 开始了可能改善认知能力的药物试验。我们的第一个这样的 试验使用了DDAVP，至少取得了一定的成功。 此外，我们还寻找了潜在的临床表现。 与糟糕的结果相关。我们发现患有这种疾病的患者 精神分裂症比其他重病精神病患者更具攻击性 患者在医院期间，以前的性侵病史是 与住院人数增加有关。关于…… 抗精神病药物治疗的主要副作用是迟发性运动障碍(TD)，我们 发现抑郁症可能与一种更严重的变异有关。

Despite wide variations in the clinical manifestations of schizophrenia, it remains difficult for clinicians to design novel treatments or predict vulnerability to negative outcomes (including medication side effects) based on signs and symptoms of the disorder. By focusing on certain clinical characteristics of schizophrenia we have designed a series of experimental medication treatments. This involves the notion that the disorder is associated with impaired cognitive performance. Hence, we have begun trials of medication that may improve cognition. Our first such trial utilized DDAVP with at least modest success. In addition we have looked for clinical manifestations potentially associated with poor outcomes. We have found that patients with schizophrenia are more assaultive than other seriously ill psychiatric patients while in the hospital and that a previous history of assaultive is associated with an increased number of hospitalizations. With regards to the major side effect of neuroleptic treatment, tardive dyskinesia (TD), we have found that depression may be associated with a more severe variant.